Successful autologous stem cell transplantation for relapsed lymphoma with peripheral blood stem cells cryopreserved for ten years.

DOI 12 References
  • Inaguma Yoko
    Department of Hematology and Medical Oncology, Fujita Health University School of Medicine
  • Handa Kousuke
    Department of Hematology and Medical Oncology, Fujita Health University School of Medicine Department of Hematology,Toyota Kosei Hospital
  • Maruyama Fumio
    Department of Hematology and Medical Oncology, Fujita Health University School of Medicine
  • Suzuki Satoshi
    Center for Advanced Medicine and Clinical Research, Nagoya University Graduate School of Medicine
  • Tsuzuki Motohiro
    Department of Hematology and Medical Oncology, Fujita Health University School of Medicine
  • Hasegawa Akio
    Department of Hematology and Medical Oncology, Fujita Health University School of Medicine
  • Yamamoto Yukiya
    Department of Hematology and Medical Oncology, Fujita Health University School of Medicine
  • Watanabe Masato
    Department of Hematology and Medical Oncology, Fujita Health University School of Medicine Department of Hematology and Oncology, Yamada Hospital
  • Akatsuka Yoshiki
    Department of Hematology and Medical Oncology, Fujita Health University School of Medicine
  • Mizuta Shuichi
    Department of Hematology and Medical Oncology, Fujita Health University School of Medicine
  • Okamoto Masataka
    Department of Hematology and Medical Oncology, Fujita Health University School of Medicine
  • Emi Nobuhiko
    Department of Hematology and Medical Oncology, Fujita Health University School of Medicine

Search this article

Abstract

High dose chemotherapy followed by autologous stem cell transplantation (SCT) has been shown to be effective therapy for patients with relapsed lymphoma responsive to standard-dose salvage chemotherapy. Here we report a patient in second complete remission(CR) from relapsed follicular lymphoma (grade 3) who was successfully treated with peripheral blood stem cells (PBSC) that had been harvested in first CR 10 years before. One of six frozen bags was thawed and submitted for progenitor cell assays. Because the number of progenitors was considered to be sufficient for engraftment, autologous SCT was performed without further stem cell harvest. At infusion, the viability of all nucleated cells (ANC) of the 5 remaining bags was 61.4%. She was expected to receive 2.87×10 8 /kg of ANC, 4.43×10 6 /kg of CD34 + cells and 32.3×10 4 /kg of CFU-GM based on the numbers obtained before cryopreservation. She achieved a granulocyte count>500/mm 3 on day 10 and a self-supporting platelet count>20×10 3 /mm 3 on day 12. She remains disease-free for 3.5 years. This successful case suggests that PBSC may be harvested at an early time point before significant stem cell damage due to chemotherapy and radiotherapy and stored for several years.

Journal

References(12)*help

See more

Keywords

Details 詳細情報について

Report a problem

Back to top